SELLAS Life Sciences Group (SLS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Jun, 2026Opening remarks and agenda
The meeting was called to order virtually, with adherence to rules of conduct and an agenda provided online.
Directors, executive officers, legal counsel, and auditors were introduced at the outset.
Board and executive committee updates
Directors and committee chairs for Compensation, Science, Audit, and Nominating & Corporate Governance were present.
The board expressed appreciation for shareholder engagement and proxy submissions.
Shareholder proposals
Five proposals were presented: re-election of two directors, ratification of auditors, amendment to the equity plan, advisory vote on executive compensation, and approval for potential meeting adjournment.
Partial view of Summaries dataset, powered by Quartr API
Latest events from SELLAS Life Sciences Group
- Pivotal AML trial data for GPS and phase II results for SLS009 are expected to drive major milestones.SLS
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA28 May 2026 - Pivotal data for GPS and SLS-009 in AML expected by year-end, backed by strong financials.SLS
A.G.P.'s Annual Virtual Healthcare Conference20 May 2026 - Imminent phase III and II data for GPS and SLS009 in AML signal major near-term catalysts.SLS
Stifel 2026 Targeted Oncology Virtual Forum19 May 2026 - Pivotal AML trials near key readouts as net loss rises and cash reserves strengthen.SLS
Q1 202612 May 2026 - Annual meeting to vote on directors, auditor, equity plan, executive pay, and governance matters.SLS
Proxy filing23 Apr 2026 - Virtual annual meeting to vote on directors, auditor, equity plan, and executive pay.SLS
Proxy filing23 Apr 2026 - Strong cash position and clinical progress in AML set stage for pivotal 2026.SLS
Q4 202519 Mar 2026 - REGAL Phase 3 interim analysis in AML will guide next steps after IDMC review in January 2025.SLS
Study Update11 Jan 2026 - Late-stage cancer drug developer registers resale of 19.7M shares tied to new warrant inducement.SLS
Registration Filing16 Dec 2025